Looks like it going to do a 100% retrace back to 27.5 cents. 95% fall from the high. No buyers left. Well done management. Naive or just plain incompetent.
NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress
Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling